Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Struggling to keep your New Year's resolutions? Here's how to keep yourself on track - 2US FDA investigates Takeda's blood disorder drug after pediatric death
- 3As tetanus vaccination rates decline, doctors worry about rising case numbers
- 44 Must-Visit bar-b-que Eateries This Year
- 5Bismuth’s haredi draft bill won’t change enlistment, IDI expert tells 'Post'
- FDA approves Wegovy pill for weight loss: What to know
- Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- 2 new malaria treatments announced as drug resistance grows
- Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- Shrewd Home Gadgets to Save Energy
- Well known Travel Booking Locales: What's Your Pick?
- In the background: Visiting Notable Film Areas All over the Planet
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
